Literature DB >> 7060750

Drug preferences in humans.

C E Johanson, E H Uhlenhuth.   

Abstract

In animals, self-administration procedures have been used to assess reinforcing properties of drugs and predict abuse liability. In humans, subjective effect have been used. In the present studies, there two approaches were combined in human subjects. During the first four sessions of a nine-session experiment, subjects were given opportunities to ingest two drugs. After ingestion, subjects were free to leave. Mood questionnaires were filled out before ingestion and 1, 3, and 6 h later. During the last five sessions, subjects chose which drug to ingest. In study I, subjects chose 5 mg d-amphetamine over placebo. Subjective effects were typical of amphetamines but were not correlated with amount of amphetamine preference. In study II this same comparison was repeated three times. The preference for amphetamine decreased but subjective effects did not change. In study III, subjects tended to prefer 5 mg d-amphetamine to 20 mg fenfluramine. Subjective effects after amphetamine were similar to those in study I but those after fenfluramine did not differ from placebo. In study IV, subjects preferred placebo to 5 or 10 mg diazepam. The subjective effects of diazepam were typical of sedatives. These results indicate that drug self-administration procedures with humans can be useful for testing abuse liability and that subjective measures do not always correlate with drug preference.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060750

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  10 in total

1.  A within-subject assessment of the discriminative stimulus and reinforcing effects of self-administered cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

2.  The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Relationship between oral D-amphetamine self-administration and ratings of subjective effects: do subjective-effects ratings correspond with a progressive-ratio measure of drug-taking behavior?

Authors:  B Levi Bolin; Anna R Reynolds; William W Stoops; Craig R Rush
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

4.  Long-Term Use of Benzodiazepines: Implications and guidelines.

Authors:  N L Potts; K R Krishnan
Journal:  Can Fam Physician       Date:  1992-01       Impact factor: 3.275

5.  Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration.

Authors:  J D Roache; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

7.  The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2010-02       Impact factor: 2.293

8.  Assessment of dependence potential of drugs in humans using multiple indices.

Authors:  C E Johanson; K Kilgore; E H Uhlenhuth
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Amphetamine-induced place preference in humans.

Authors:  Emma Childs; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2008-12-25       Impact factor: 13.382

Review 10.  Advancing stem cell therapy from bench to bedside: lessons from drug therapies.

Authors:  Thekkeparambil Chandrabose Srijaya; Thamil Selvee Ramasamy; Noor Hayaty Abu Kasim
Journal:  J Transl Med       Date:  2014-09-04       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.